Drugs / UCART22
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04150497 | Oct 2019 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia | Cellectis S.A. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCART22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04150497 ↗ |
| Modality | Cell therapy | “Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor” NCT04150497 ↗ |
| Route | Intravenous | “UCART22 administered intravenously” NCT04150497 ↗ |
| Target | CD22 | “anti-CD22 Chimeric Antigen Receptor” NCT04150497 ↗ |